Last reviewed · How we verify
LifeBridge Health — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Bivalirudin with and without eptifibatide | Bivalirudin with and without eptifibatide | marketed | Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) | Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor | Cardiovascular | |
| Arixtra | Arixtra | marketed | Antithrombin-III, Coagulation factor X | Cardiovascular | ||
| Fascia Iliaca Nerve Block | Fascia Iliaca Nerve Block | marketed | Pain Management / Regional Anesthesia |
Therapeutic area mix
- Cardiovascular · 2
- Pain Management / Regional Anesthesia · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for LifeBridge Health:
- LifeBridge Health pipeline updates — RSS
- LifeBridge Health pipeline updates — Atom
- LifeBridge Health pipeline updates — JSON
Cite this brief
Drug Landscape (2026). LifeBridge Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lifebridge-health. Accessed 2026-05-17.